A $330 million Series B that closed oversubscribed is notable on its own terms, but the more telling detail is who wrote the checks: ARCH Venture Partners co-led alongside TCGX, with a16z Bio+Health, Blackstone Multi-Asset Investing, CPP Investments, RA Capital, T. Rowe Price, and a sovereign wealth fund all participating. That is a crossover syndicate built for a public exit, not a biotech curiosity round. Ollin Biosciences, founded just three years ago in 2023, has assembled institutional credibility that most ophthalmology startups spend a decade chasing.
The scientific premise is aggressive in the best way. OLN324 is engineered with substantially higher Ang2 potency relative to faricimab, the VEGF/Ang2 bispecific that Genentech brought to market in January 2022 and that quickly became a commercial anchor in retina. The molecule also carries increased molar dosing compared to both faricimab and Eylea HD, the 8 mg aflibercept formulation FDA approved in August 2023. The head-to-head 164-patient JADE proof-of-concept study showed OLN324 produced faster and greater retinal drying versus faricimab in both DME and wet AMD, with numerically greater vision gains. That is a clean signal from a randomized comparator study, and it is the kind of data that justifies a $330 million bet rather than a cautious dose-finding exercise.
The commercial logic is straightforward. Ollin cites a $15 billion retina market, and the DME segment alone was valued at roughly $3.4 billion in 2026. Phase 3 trials in both DME and wet AMD are set to begin in the second half of 2026, following a completed End-of-Phase 2 FDA meeting and EMA scientific advice. Through the Innovent partnership, the program will extend into China and South Korea, broadening both the enrollment pool and eventual revenue geography. Innovent, which discovered the molecule, retains both a financial stake and deep manufacturing infrastructure, which compresses the usual execution risk that derails ex-China biotech buildouts.
The single number to track from here is the interval-extension data from Phase 3. If OLN324 can demonstrate durable retinal control at every-16-week or longer dosing intervals in a registrational dataset, the label would immediately separate it from the existing competitive field on durability grounds, and payer conversations change entirely. Anatomic superiority in 164 patients is a hypothesis; durability over a 52-week Phase 3 primary endpoint is the proof the market requires before repricing this asset.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
